India Seeks Public Input to Stop Misleading Pharma Brand Names

In a move that could reshape how medicines are marketed in the country, the Ministry of Health and Family Welfare has launched a public‑consultation draft to curb the use of misleading pharmaceutical brand names. The call, posted on the Ministry’s website, asks doctors, pharmacists, patients and industry players to share their thoughts before the final rules are fixed.

Why the buzz? Too often, patients receive prescriptions that are hard to read, and pharmacists end up dispensing the wrong drug because two brand names look almost identical or sound alike. A classic example that has popped up in recent years involves two antihistamines whose names differ by just a single letter – a mistake that could lead to unnecessary side‑effects or a lack of relief.

“We are not trying to stifle legitimate branding,” said a senior official from the Department of Health. “But when a brand name is practically a clone of an existing one, it creates a real risk of medication errors, especially in busy clinics where time is short.”

The draft guidelines propose a few concrete steps: manufacturers must submit the proposed brand name to the Central Drugs Standard Control Organization (CDSCO) for prior approval, and the name must pass a ‘look‑alike, sound‑alike’ test against all already‑registered names. If the name fails, the company would need to pick a different one or face a fine.

Beyond the procedural changes, the Ministry also hinted at a tougher enforcement regime. Repeated violations could lead to suspension of the product’s licence, a measure that has drawn mixed reactions from the pharma lobby.

Industry bodies have welcomed the effort to bring clarity, yet they caution that the new process should not become a bureaucratic maze. “We support patient safety, but the approval mechanism must be swift and transparent,” a spokesperson from the Indian Pharmaceutical Association said.

The public consultation is open until 30 September 2026. Stakeholders can submit written comments, case studies or suggestions through the Ministry’s online portal. The final guidelines are expected to be rolled out early next year, once the feedback is analysed and incorporated.

For patients and healthcare professionals alike, the hope is simple: fewer mix‑ups at the pharmacy counter and safer treatment outcomes. Whether the new rules will deliver on that promise remains to be seen, but the fact that the conversation has started is, perhaps, a step in the right direction.